
Epizyme EPZM
Quartalsbericht 2022-Q2
hinzugefügt 09.08.2022
Epizyme Betriebsaufwand 2011-2025 | EPZM
Betriebsaufwand Jährlich Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 236 M | 201 M | 150 M | 147 M | 120 M | 135 M | 96.5 M | 71.6 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 236 M | 71.6 M | 145 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
96.2 M | $ 4.72 | 0.96 % | $ 783 M | ||
|
Aclaris Therapeutics
ACRS
|
92.7 M | $ 3.32 | -1.19 % | $ 257 M | ||
|
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 25.26 | -2.47 % | $ 1.22 B | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 209.93 | -0.11 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
20.7 M | $ 1.31 | -1.88 % | $ 7.14 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.4 | -0.71 % | $ 8.18 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
AstraZeneca PLC
AZN
|
17.6 B | $ 89.77 | -0.57 % | $ 96.9 B | ||
|
Anika Therapeutics
ANIK
|
51.6 M | $ 9.59 | 1.05 % | $ 141 M | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | ||
|
Biogen
BIIB
|
5.39 B | $ 174.05 | 0.9 % | $ 25.3 B | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.33 | 2.08 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | ||
|
Baudax Bio
BXRX
|
54.6 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
Benitec Biopharma
BNTC
|
9.83 M | $ 12.26 | -5.4 % | $ 505 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 94.78 | -1.28 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
53.9 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
1.18 B | $ 570.12 | -1.88 % | $ 43.2 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 0.28 | -2.76 % | $ 609 M | ||
|
Catalyst Biosciences
CBIO
|
176 M | $ 14.66 | -4.25 % | $ 965 M | ||
|
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
425 M | - | -7.23 % | $ 13 M | ||
|
BioVie
BIVI
|
18.1 M | $ 1.47 | -2.55 % | $ 2.17 M | ||
|
Cortexyme
CRTX
|
34.6 M | - | -1.05 % | $ 67.1 M | ||
|
Celldex Therapeutics
CLDX
|
58.1 M | $ 27.54 | -1.43 % | $ 1.77 M | ||
|
Cellectar Biosciences
CLRB
|
15.3 M | $ 3.61 | -4.5 % | $ 44.1 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.07 B | $ 11.3 | -1.22 % | $ 731 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
34.4 M | - | -5.68 % | $ 8.28 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Enochian Biosciences
ENOB
|
189 M | - | - | $ 40.5 M | ||
|
Cerus Corporation
CERS
|
135 M | $ 2.15 | -0.23 % | $ 397 M | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K |